Clinical Scorecard: Semaglutide Use Linked to Erythromelalgia Remission
At a Glance
Category
Detail
Condition
Erythromelalgia, a rare neurovascular pain disorder characterized by episodic erythema, increased skin temperature, and burning pain
Key Mechanisms
Microvascular dysfunction and functional sensory dysregulation; potential GLP-1 receptor agonist effects include anti-inflammatory action, modulation of nociceptive signaling, and improved endothelial function
Target Population
Patients with erythromelalgia, including those with obesity and complex medical histories
Care Setting
Outpatient clinical management with specialist follow-up
Key Highlights
A 46-year-old female with 4-year erythromelalgia experienced complete symptom remission after initiation of semaglutide therapy.
Symptom resolution occurred rapidly, prior to significant weight loss, suggesting a pharmacologic effect of GLP-1 receptor agonists.
Repeat sensory testing and clinical examination confirmed normalization of thermal thresholds and resolution of erythema and swelling.
Guideline-Based Recommendations
Diagnosis
Clinical diagnosis based on episodic burning pain, erythema, and heat intolerance, often triggered by heat or exertion.
Exclude small-fiber neuropathy via skin biopsy and nerve conduction studies.
Use quantitative sensory testing to assess thermal detection thresholds.
Management
Consider GLP-1 receptor agonist therapy such as semaglutide for erythromelalgia, especially in patients with obesity.
Prior treatments may include aspirin and symptomatic relief measures; monitor for adverse effects of other agents like misoprostol.
Avoid or cautiously use gabapentin, pregabalin, or antidepressants if adverse effect concerns exist.
Monitoring & Follow-up
Monitor symptom frequency, severity, and triggers through patient report and clinical examination.
Perform repeat quantitative sensory testing to assess changes in thermal thresholds.
Track weight and BMI changes during GLP-1 receptor agonist therapy.
Risks
Potential adverse effects of GLP-1 receptor agonists include gastrointestinal symptoms; monitor accordingly.
Limitations in evidence exist due to single case report; causality not established.
Consider individual patient comorbidities and contraindications before initiating therapy.
Patient & Prescribing Data
Middle-aged adults with erythromelalgia and comorbid obesity and vascular risk factors.
Semaglutide initiated at 0.25 mg weekly, titrated to 1 mg weekly, led to complete symptom remission by week 4 and sustained remission over 15 months with significant weight loss.
Clinical Best Practices
Perform comprehensive neurologic and vascular evaluation to exclude other causes of symptoms.
Use GLP-1 receptor agonists as a potential novel therapy for erythromelalgia, recognizing current evidence is limited to case reports.
Monitor patients closely for symptom response and adverse effects during treatment.
Document clinical and sensory testing changes to support therapeutic decisions.
Encourage further research and controlled studies to validate GLP-1 receptor agonists in neurovascular pain syndromes.
Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.
